Clinical Trials Logo

Epithelioid Sarcoma clinical trials

View clinical trials related to Epithelioid Sarcoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05415098 Recruiting - Gastric Cancer Clinical Trials

Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas

Start date: September 30, 2022
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label, Phase 1 study that will be conducted in two parts. Part 1 is the dose escalation of APG-5918. Part 2 is the dose expansion of APG-5918. APG-5918 will be administered orally. Patients will be treated in 28-day cycles.

NCT ID: NCT05407441 Recruiting - Chordoma Clinical Trials

Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors

Start date: August 10, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This research study involves a combination of three drugs given together as a possible treatment for malignant rhabdoid tumor, atypical teratoid rhabdoid tumor, epithelioid sarcoma, chordoma or other tumors that are deficient in one of two possible proteins, either INI-1 (SMARCB1) or SMARCA4. The names of the study drugs involved in this study are: - Tazemetostat (TAZVERIK) - Nivolumab (OPDIVO) - Ipilimumab (YERVOY)

NCT ID: NCT05286801 Recruiting - Clinical trials for Malignant Solid Neoplasm

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

Start date: November 17, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies how well tiragolumab and atezolizumab works when given to children and adults with SMARCB1 or SMARCA4 deficient tumors that have either come back (relapsed) or do not respond to therapy (refractory). SMARCB1 or SMARCA4 deficiency means that tumor cells are missing the SMARCB1 and SMARCA4 genes, seen with some aggressive cancers that are typically hard to treat. Immunotherapy with monoclonal antibodies, such as tiragolumab and atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT04416568 Recruiting - Epithelioid Sarcoma Clinical Trials

Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers

Start date: August 14, 2020
Phase: Phase 2
Study type: Interventional

This clinical trial is studying two immunotherapy drugs (nivolumab and ipilimumab) given together as a possible treatment for INI1-negative tumors.

NCT ID: NCT04390737 Recruiting - Clinical trials for Advanced Solid Tumor

Evaluate the Safety and Clinical Activity of HH2853

Start date: September 8, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, multicenter, first-in-human phase I/II study which is composed of 3 parts: phase I dose escalation, phase I dose extension and phase II. HH2853 will be administered orally on a continuous BID schedule on a continuous 28-day treatment cycle.

NCT ID: NCT04008238 Recruiting - Synovial Sarcoma Clinical Trials

Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients

PIPER
Start date: January 6, 2020
Phase: N/A
Study type: Interventional

This is a biology driven, monocentric study, designed to identify biomarkers of activity of trabectedin in patients with advanced non-L soft-tissue sarcoma. The aim of this study is to implement high-throughput profiling technologies to identify predictive biomarkers of trabectedin efficacy through sequential tumor biopsies and blood sample collection in sarcoma patients.

NCT ID: NCT03967834 Recruiting - Soft Tissue Sarcoma Clinical Trials

Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group

MIRAS
Start date: April 26, 2021
Phase: N/A
Study type: Interventional

This trial is a translational, open-label, multi-sites, prospective and retrospective cohort study of 500 patients aimed at clinical and biological characterization of sarcoma of rare subtype. 400 patients will be included in this prospective cohort study; they will be identified in the investigating centers in the context of either routine care or a clinical study protocol. Retrospective cases of patients (100 cases in total) will be identified in all centers through the GSF/GETO clinical databases already setted up (including the clinical base Conticabase).

NCT ID: NCT03099681 Recruiting - Epithelioid Sarcoma Clinical Trials

An Observational Study on Epithelioid Sarcoma

EPISObs
Start date: August 22, 2017
Phase:
Study type: Observational

Prospective Italian study aimed to provide a description of the population affected by Epithelioid Sarcoma (ES)